That was higher than its previous bid of up to $9 billion which sparked a lawsuit from pfizer. For up to $10 billion, prevailing over novo nordisk a/s in a tumultuous bidding war after us regulatory opposition thwarted the danish drugmaker’s rival. The announcement of the deal signaled an end to the bidding war for metsera between pfizer and novo nordisk, the danish maker of ozempic and wegovy.
Vil i se @Casper Krause 2 og jeg tage | Enulie porer😈 (@enulie_porer_)
Metsera accepted a sweetened offer from.
Under terms of a deal announced late friday, pfizer will acquire metsera for up to $86.25 per share, or more than $10 billion.
Pfizer wins $10 billion bid for metsera, securing entry into the booming obesity drug market Novo nordisk withdraws over us antitrust risks after a heated bidding war. Agreed to buy metsera inc
